Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Insulinotropic Effect of New Glibenclamide Isosteres

R. Ouedraogo, Q.-A. Nguyen, M.-H. Antoine, C. Kane, M.J. Dunne, L. Pochet, B. Masereel and P. Lebrun
Journal of Pharmacology and Experimental Therapeutics May 1999, 289 (2) 625-631;
R. Ouedraogo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Q.-A. Nguyen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.-H. Antoine
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Kane
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.J. Dunne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Pochet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Masereel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Lebrun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The aim of the present study was to characterize the effects of BM 208 (N-[4-(5-chloro-2-methoxybenzamidoethyl)benzenesulfonyl]-N′-cyano-N"-cyclohexylguanidine) and BM 225 (1-[4-(5-chloro-2-methoxybenzamidoethyl)benzene sulfonamido]-1-cyclohexylamino-2-nitroethylene), two newly synthesized isosteres of glibenclamide, on ionic and secretory events in rat pancreatic islet cells. Both compounds inhibited 86Rb (42K substitute) outflow from rat pancreatic islets perifused throughout at low (2.8 mM) d-glucose concentration. In excised inside-out membrane patches, BM 208 and BM 225 reduced the frequency of KATP + channel openings. The inhibition of 86Rb outflow induced by BM 208 and BM 225 coincided with an increase in 45Ca outflow. The latter phenomenon was abolished in islets exposed to Ca2+-free media. Both isosteres of glibenclamide increased the [Ca2+]i in single pancreatic islet cells. This effect was counteracted by verapamil, a Ca2+ entry blocker. In islets exposed to 2.8 mM glucose and extracellular Ca2+, BM 208 and BM 225 stimulated insulin output. The secretory capacity of BM 225 was more marked than that of BM 208, but the time courses of the cationic and secretory responses exhibited obvious dissociations. These data suggest that the secretory capacity of BM 208 and BM 225 results, at least in part, from the inhibition of ATP-sensitive K+ channels with subsequent increase in Ca2+ inflow. The dissociation between cationic and secretory variables further suggests that the modifications in Ca2+ handling are not solely attributable to a primary inhibition of the ATP-sensitive K+ channels.

Footnotes

  • Send reprint requests to: Dr. P. Lebrun, Laboratory of Pharmacology, Faculty of Medicine (CP 617), Université Libre de Bruxelles, Route de Lennik 808, B-1070 Brussels, Belgium.

  • ↵1 This work was supported in part by grants from the National Fund for Scientific Research (Belgium), the British Diabetic Association, and the University of Sheffield Research Fund (UK); by a grant-in-aid from the Université Libre de Bruxelles and from Burkina Faso (to R.O.); and by a grant-in-aid from the UniversitéLibre de Bruxelles (to Q.-A.N.).

  • Abbreviations:
    BM 208
    N-[4-(5-chloro-2-methoxybenzamido ethyl)benzenesulfonyl]-N′-cyano-N"-cyclohexylguanidine
    FOR
    fractional outflow rate
    [Ca2+]i
    intracellular Ca2+ concentration
    KATP+
    ATP-sensitive K+
    BM 225
    1-[4-(5-chloro-2-methoxybenzamidoethyl)benzenesulfonamido]-1-cyclo-hexylamino-2-nitroethylene
    • Received November 24, 1998.
    • Accepted November 24, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (2)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 2
1 May 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Insulinotropic Effect of New Glibenclamide Isosteres
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Insulinotropic Effect of New Glibenclamide Isosteres

R. Ouedraogo, Q.-A. Nguyen, M.-H. Antoine, C. Kane, M.J. Dunne, L. Pochet, B. Masereel and P. Lebrun
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 625-631;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Insulinotropic Effect of New Glibenclamide Isosteres

R. Ouedraogo, Q.-A. Nguyen, M.-H. Antoine, C. Kane, M.J. Dunne, L. Pochet, B. Masereel and P. Lebrun
Journal of Pharmacology and Experimental Therapeutics May 1, 1999, 289 (2) 625-631;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by 4-Aminoquinolines and Other Weak Bases: Mechanistic Studies
  • Pharmacodynamics of Immunosuppression by Mycophenolic Acid: Inhibition of Both Lymphocyte Proliferation and Activation Correlates with Pharmacokinetics
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics